The intersection of pharmacology and dentistry represents a critical area of clinical practice that directly influences treatment outcomes and patient safety. Medications prescribed for systemic conditions frequently produce oral side effects and can dramatically alter the dental treatment landscape. Understanding these interactions requires knowledge of how drugs affect salivary glands, periodontal tissues, bone metabolism, and oral microbiology.

Xerostomia and Salivary Dysfunction

Medication-induced xerostomia affects approximately 25-30% of patients taking multiple medications and represents one of the most common oral side effects in clinical practice. The mechanism is multifaceted: anticholinergic medications inhibit parasympathetic stimulation of salivary glands, diuretics reduce systemic fluid volume, and antidepressants alter neurotransmitter signaling in salivary tissue. Tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs) are particularly problematic, with over 40% of users experiencing reduced saliva production.

The consequences extend far beyond discomfort. Saliva serves protective functions: buffering acid, providing antimicrobial activity through proteins like lactoferrin and lysozyme, and maintaining oral pH. When salivary flow diminishes below 0.5 mL/minute (hyposalivation), caries risk increases dramatically. Patients develop rapid onset cavities, often at the cervical line, sometimes requiring full-mouth restoration. Additionally, xerostomia predisposes to oral candidiasis by eliminating the antifungal environment normally maintained by healthy saliva. Clinical management requires comprehensive approach: stimulating residual salivary function through sugar-free lozenges, using salivary substitutes, applying fluoride treatments, and potentially adjusting medications with physician consultation.

Gingival Overgrowth and Periodontal Effects

Certain medications trigger gingival overgrowth (also termed drug-induced gingival hyperplasia) through fibroblast proliferation and altered collagen metabolism. Calcium channel blockers including nifedipine, diltiazem, and verapamil cause overgrowth in 3-10% of users. Phenytoin (Dilantin), historically a common cause, still produces hyperplasia in 50% of chronic users. Immunosuppressants like cyclosporine and tacrolimus similarly trigger dramatic gingival changes. The mechanism involves altered tissue remodeling, with enhanced collagen synthesis exceeding normal degradation, combined with diminished control of inflammatory mediators.

Clinically, overgrowth appears as enlarged, fibrotic gingival tissues that create functional and aesthetic problems. Beyond appearance, these enlarged tissues create pseudo-pockets harboring plaque and calculus, accelerating periodontal disease. The treatment challenge is significant: mechanical removal through gingivectomy provides temporary improvement, but recurrence is common unless the causative medication is discontinued. Maintenance requires aggressive plaque control and possibly topical antimicrobial therapy. For patients requiring continued use of these medications, the preventive strategy emphasizes enhanced home care, chlorhexidine rinses (though limited to short-term use due to staining), and frequent professional cleanings every 3-4 months rather than standard 6-month intervals.

Anticoagulation and Hemorrhage Considerations

Patients on anticoagulants including warfarin, direct oral anticoagulants (DOACs like apixaban and rivaroxaban), and dual antiplatelet therapy (aspirin plus clopidogrel) present unique challenges for dental treatment. The bleeding risk is not absolute—many dental procedures can be performed safely without interruption of therapy when proper hemostasis measures are employed. However, complex extractions, periodontal surgery, and implant procedures require careful planning and communication with prescribing physicians.

Current evidence supports continuing anticoagulation for most minor procedures including routine restorative care, scaling and root planing, and routine extractions. For complex cases, the risk-benefit analysis may favor temporary anticoagulation modification, but this represents a medical decision beyond dental scope. Local hemostatic measures become paramount: use of pressure packs with collagen matrices, topical thrombin, and topical hemostatic agents like tranexamic acid. Post-operative instructions must emphasize avoiding disruption of clots, abstaining from rinsing for 24 hours, and avoiding smoking, alcohol, and strenuous activity. Patients should receive written instructions and understand warning signs requiring emergency evaluation.

Bisphosphonates, widely prescribed for osteoporosis and malignancy-related hypercalcemia, present a distinct challenge through medication-related osteonecrosis of the jaw (MRONJ). These medications inhibit osteoclast-mediated bone resorption by blocking farnesyl pyrophosphate synthase in the mevalonate pathway, causing pro-apoptotic effects in bone cells. While the incidence is relatively low (0.001-0.01% in osteoporosis patients versus 1% in cancer patients receiving IV formulations), the consequences are severe.

MRONJ typically presents as exposed bone, often following dental extraction or other traumatic oral events, but can occur spontaneously. The affected area becomes painful, resistant to healing, and prone to secondary infection. Management is primarily preventive: patients should receive comprehensive dental evaluation and treatment before initiating bisphosphonate therapy. Once therapy has begun, avoid unnecessary tooth extractions when possible. If extraction becomes necessary, consider surgical flaps, primary closure, and prophylactic antibiotics. High-risk patients (cancer patients on IV bisphosphonates for >3 years, those with poor oral hygiene) warrant more aggressive preventive protocols and periodic monitoring. Drug holidays lasting 1-2 years may be considered in osteoporosis patients who have achieved adequate bone density, as osteonecrosis risk diminishes significantly after medication discontinuation.

Gingival Hyperplasia from Immunosuppressants

Beyond calcium channel blockers, immunosuppressive agents used in transplant patients and those with autoimmune conditions produce significant gingival changes. Cyclosporine causes hyperplasia in 25-30% of transplant recipients, creating massive overgrowth that can obscure occlusal relationships and cause speech impairment. The mechanism involves altered T-cell function and enhanced fibroblast activity. Newer agents like tacrolimus and sirolimus produce less gingival overgrowth but still carry risk.

Management of immunosuppressant-related changes requires multidisciplinary coordination. The hyperplasia often responds poorly to mechanical treatment alone and frequently recurs despite excellent plaque control. Surgical removal remains the primary option, with advanced techniques including electrocautery and laser-assisted gingivectomy showing improved healing and reduced recurrence compared to scalpel surgery. Ongoing surveillance and maintenance of meticulous oral hygiene remain essential, as recurrence rates approach 80% without consistent prevention.

Drug-Induced Candidiasis

Corticosteroids, particularly when inhaled for asthma or COPD, cause oral candidiasis by suppressing local immune function and altering normal bacterial flora. Additionally, chemotherapy drugs and immunosuppressants increase candidiasis risk. Clinical presentation includes erythematous patches, white pseudomembranous coating, or angular cheilitis (inflammation at mouth corners). Symptoms range from asymptomatic to painful dysgeusia and difficulty eating.

Treatment involves topical antifungals—clotrimazole troches, nystatin suspension, or miconazole gel—applied after thorough plaque removal. Systemic antifungals like fluconazole are reserved for severe or refractory cases. Prevention centers on patient education: rinsing mouth after inhaled corticosteroid use, regular oral hygiene, denture care, and avoiding irritants. Some patients benefit from probiotic lozenges containing Lactobacillus species, which may restore beneficial flora and reduce candidiasis recurrence.

Clinical Documentation and Medication Review

Comprehensive medication history represents essential defensive dentistry. This includes all medications, supplements, and herbal products, with documentation of dosages and duration. Many patients omit over-the-counter medications and supplements when questioned, requiring specific inquiry about antihistamines, NSAIDs, oral anticoagulant supplements, and Chinese medicines.

Clinically significant interactions should be flagged in the treatment record. When patient medications appear problematic, consultation with the prescribing physician is appropriate before treatment modification. This communication should be professional and specific: "Patient is taking nifedipine, and I'm noting significant gingival overgrowth. Have you considered alternative antihypertensives, and should I implement enhanced prevention protocols?" Such collaboration improves overall patient care and demonstrates professional coordination.

Summary

Medications profoundly influence oral health through multiple mechanisms affecting saliva, periodontal tissues, bone metabolism, and microbiology. Successful dental management requires understanding these interactions and implementing appropriate preventive and treatment strategies. Comprehensive medication review, early identification of potential complications, and close collaboration with medical providers form the foundation of safe and effective care in this complex patient population. Individual circumstances vary significantly based on specific medications, dosages, duration of use, and concurrent conditions, making personalized treatment planning essential for optimal outcomes.